Towards the use of monodisperse ferromagnetic particles in low resource malaria diagnostic devices by Baglia, Mark Louis
 
 
TOWARDS THE USE OF MONODISPERSE FERROMAGNETIC PARTICLES IN LOW 
RESOURCE MALARIA DIAGNOSTIC DEVICES 
 
By 
Mark L. Baglia 
 
Thesis 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
MASTER OF SCIENCE 
in 
Biomedical Engineering 
May, 2016 
Nashville, Tennessee 
 
 
Approved: 
Frederick R. Haselton, Ph.D. 
David W. Wright, Ph.D.
ii 
 
ACKNOWLEDGEMENTS 
I would like to thank everyone who has helped me through the process of completing this thesis 
including all of the members of Rick Haselton’s lab. I’d especially like to thank Rick for being 
patient with me as my thesis has pivoted several times and as I’ve been out of the lab working 
on my MBA. I’d also like to thank my wife, Michelle, for always encouraging me to finish my 
Master’s despite the many times I wanted to quit. Without her encouragement, I never would 
have finished.  
iii 
 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS ....................................................................................................................ii 
 
LIST OF FIGURES .............................................................................................................................. iv 
 
I.  LOW RESOURCE DIAGNOSTICS AND STUDY RATIONALE ............................................................ 1 
 
Introduction ................................................................................................................................ 1 
Malaria Overview .................................................................................................................... 4 
Infection and Pathogenesis ................................................................................................. 5 
Diagnostic Methods ............................................................................................................ 8 
Treatment and Prognosis .................................................................................................. 10 
Low-Resource Diagnostics .................................................................................................... 12 
Problem ..................................................................................................................................... 15 
Biomarker Concentration Design .............................................................................................. 16 
 
II.  DEVELOPMENT OF A MAGNETIC BEAD BASED FLUID TRANSFER SYSTEM .............................. 19 
 
Introduction .............................................................................................................................. 19 
Hypothesis................................................................................................................................. 20 
Introduction .............................................................................................................................. 20 
Methods .................................................................................................................................... 22 
Standard Curve Determination ............................................................................................. 22 
Sample Preparation .............................................................................................................. 22 
Drop experiment ................................................................................................................... 23 
Sample Analysis ..................................................................................................................... 26 
Results ....................................................................................................................................... 28 
Standard curves and Calibration ........................................................................................... 28 
Bead Transfer distance ......................................................................................................... 32 
Transferred bead mass ......................................................................................................... 33 
Discussion.................................................................................................................................. 35 
Future Directions ...................................................................................................................... 38 
 
REFERENCES .................................................................................................................................. 40 
 
  
iv 
 
LIST OF FIGURES 
Figure                Page 
1. Malaria life cycle ......................................................................................................................... 6 
2. Giemsa stained gametocytes of the P. falciparum parasite ....................................................... 9 
3. Giemsa stained P. vivax trophozoite .......................................................................................... 9 
4. Patient sample loading ............................................................................................................. 16 
5. Micro-particle transfer .............................................................................................................. 17 
6. Transferred micro-particle elution ........................................................................................... 17 
7. Goniometer-based high-speed video test fixture ..................................................................... 24 
8. Transferred Fluid volume vs. Loaded bead mass ..................................................................... 30 
9. Fluid transfer variability ............................................................................................................ 31 
10. Fluid transfer efficiency .......................................................................................................... 32 
11. Bead transfer distance ............................................................................................................ 33 
12. Transferred bead mass ........................................................................................................... 34 
13. Bead transfer efficiency .......................................................................................................... 34 
14. Transfer efficiency and transfer distance ............................................................................... 36 
15. Transfer efficiency and total fluid transfer. ............................................................................ 38 
 
 
 
 1 
 
CHAPTER I 
LOW RESOURCE DIAGNOSTICS AND STUDY RATIONALE 
Introduction 
Throughout the developing world, infectious diseases have a much greater impact than 
what we are used to in developed countries. Many historically prevalent diseases still persist and 
have a major impact on the populations’ overall health and the country’s economy. Malaria is 
one such disease, infecting an estimated 207 million people and causing 627,000 deaths globally 
in 2012. Approximately 90% of these deaths occurred in the sub-Saharan Africa region. While 
wealthy nations have had success against all but eradicating malaria, lower resource countries 
are still fighting the disease. Containment strategies such as mosquito nets and anti-malarial 
therapies can be effective, but despite the relatively low cost of these strategies, the scale at 
which they must be rolled out creates an economic burden on endemic countries. Additionally, 
these prophylactic measures take precious and limited resources away from therapeutic 
measures. This measure could be greatly alleviated through continued increases in the use of 
rapid diagnostic tests. In 2012, there were approximately as many doses of artemisinin-based 
combination therapy (ACT) given for malaria therapy as there were diagnostic tests run, however, 
only 50% of diagnostic tests came back positive. In fact, in the African region, if universal testing 
of all suspected malaria cases were implemented, the need for ACT treatments would be reduced 
by over 60%. This unneeded use of anti-malarial drugs creates undue economic stress on the 
native country and wasting scarce resources which could be used for preventive measures. This 
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makes a low-cost, early, and accurate diagnosis a necessity for an effective anti-malaria 
campaign. 
While reference laboratories capable of advanced diagnostics are present in malaria 
endemic regions, they are generally in urban centers, far removed from those areas most 
affected by malaria. Additionally, these laboratories are generally capacity constrained at their 
current levels of testing. As such, point-of-care (POC) testing is the most effective way to make 
an impact on the spread of malaria. POC tests currently exist predominantly as lateral flow 
immunochromatographic rapid-diagnostic-tests (RDTs). These devices generally rely on capillary 
driven lateral flow through a piece of nitrocellulose in which antibodies against malaria 
biomarkers are immobilized. Captured analyte is concentrated in a discrete line where it builds 
up to produce a visually detectable line as the signal. The most commonly used target is the 
histidine rich protein (HRP) biomarker which can be one of several proteins secreted by 
Plasmodium falciparum which are extremely rich in histidine residues. Currently available RDTs 
vary greatly in their ability to effectively detect malaria especially at low parasetemia levels. 
In fact, current RTDs do not regularly meet the performance criteria set forth by the World 
Health Organization (WHO), a lower limit of detection of 200 parasites/µL (0.1.-1nM pfHRPII in 
blood [1-3]). The WHO’s testing of malaria RDTs found that while most performed well at high 
levels of parasetemia (2000-5000 parasites/µL), only three RDTs out of 232 tested were able to 
detect 200 parasites/µL 95% of the time with ≤ 2% false positives. Even if the criteria are reduced 
to 90% detection ≤ 5% false positives, only 36 of the RDTs were effective. [4].  
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While RDTs and other POC tools may never fully replace reference laboratories for malaria 
diagnosis (lower limit of 5-20 parasites/µL) they can serve as a very effective triage to direct 
patients with malaria to ADTs and febrile patients without malaria to the appropriate treatment 
for their respective ailment. The next generation of RDTs needs to make evolutionary advances 
towards detecting increasingly lower parasetemia levels to effectively identify those infected 
with the parasite including asymptomatic individuals. However, revolutionary changes are 
needed to address the shortcomings of current RDTs which come necessarily with their use of 
antibodies as analyte targets while maintaining the test in a format that does not rely on 
infrastructure or trained operators and is still inexpensive and widely accessible in remote 
regions.  
Towards this end, we propose a method by which a patient sample can be concentrated 
by the use functionalized magnetic beads. Sample fluid is transferred across a gap to a surface 
both through its capture in the interstitial spaces between transferred micro-particles and by its 
attachment to the surface of the functionalized beads. The beads used are functionalized with 
nickel nitrilotriacetic acid (Ni-NTA) which coordinates with the histidine rich protein (HRP) malaria 
biomarker.  
Towards development of this process, we first establish the ability of non-functionalized 
magnetic micro-particles to transfer liquid solution across a distance using the strong magnetic 
field emitted by a neodymium magnet as the motive force. Next, through the use of 
functionalized magnetic particles, we attach fluorescein isothiocyanate (FITC) functionalized 
poly-l-histidine (PLH) to the particles and then use the same magnetic field method to transfer 
micro-particles. The PLH is then released from the beads by suspension in imidazole and 
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fluorescence is measured in order to ascertain the amount of PLH transferred. Through this 
method, we can concentrate biomarkers from the sample and then deposit them on an RDT 
enabling delivery of a higher concentration of biomarkers and therefore amplifying the signal on 
the RDT above that which would have come from an un-processed sample. In this study we utilize 
ideal solutions in order to prove out the concept of transferring beads from a sample tube to a 
surface utilizing a magnetic field as the motive force. Once the concept has been proven out, 
further studies must be performed to assess the effectiveness of this method using actual patient 
samples. This thesis addresses the transfer of micro-particles using a strong magnetic field and 
models the settling of those particles within a tube prior to use to begin parameter optimization 
and to ensure that particles are completely transferred to the base of the particle chamber before 
fluid transfer. 
Malaria Overview 
Malaria is an infectious disease occurring in both humans and other vertebrate species. It 
is caused by members of the Plasmodium genus, a member of the Protista kingdom. The illness 
is classified as a vector-borne illness transmitted via infected female mosquitos. The infective 
organism is present in the saliva of the host mosquito and is introduced into the blood stream of 
the secondary host’s circulatory system during the mosquito’s feeding process. The organism 
travels through the circulatory system eventually taking residence in the liver where it matures 
and reproduce. The resulting disease is typified by fever and headache with severe cases 
progressing to coma and death.  Malaria is most widespread in a broad band of tropical and 
subtropical climates along the equator. [5]. 
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Infection and Pathogenesis 
Mosquito Life Cycle 
Human malaria infections most commonly arise from five members of the Plasmodium 
genus, P. vivax, P. ovale, P. falciparum, P. malaria, and P. knowlesii [6, 7] Amongst these species, 
P. falciparum, is by far the most common in humans (~75%) followed by P. vivax (~20%)[8].  
Malaria parasites move through the environment from species to species through the use of a 
transmission vector (mosquitoes of the Anapheles genus) and a secondary vertebrate host. The 
parasites move from an infected host to the vector mosquito as part of the mosquito’s blood 
meal. After ingestion, the parasite sporozoites enter the mosquito’s salivary glands where they 
eventually differentiate further into gametocytes and then into male and female gametes in the 
mosquito’s gut. Within the gut, the male and female gametes fuse to produce an ookinete which 
penetrates the lining of the gut and forms an oocyst in the gut wall. Upon rupturing, the oocyst 
releases sporozoites which migrate back to mosquito’s salivary glands.[9, 10]. It is this sporozoite 
form of the parasite which can be then transmitted to the vertebrate secondary host while the 
mosquito feeds, leading to infection and clinical symptoms we know to be indicative of malaria. 
The full life cycle of the malaria parasite can be seen in Figure 1 [11].  
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Figure 1: Malaria life cycle - Plasmodium parasites enter the body as sporozoites and travel to the liver where they multiply and 
differentiate into merozoites. The merozoites then burst their host hepatocytes and travel into the blood stream to infect 
erythrocytes. Some then further differentiate into male and female gametocytes which can be ingested by a mosquito during 
feeding and restart the cycle after sexually reproducing in the mosquito’s gut.  
Transmission 
The primary mode of transmission is by the bites of female mosquitos of 30-40 out of the 
430 species of the Anopheles genus. When the mosquito bites the host, the sporozoites are 
injected into the vertebrate’s skin alongside the mosquito’s saliva. This transmission only occurs 
via female mosquitos since only female mosquitoes feed on blood. Mosquitoes serve as effective 
vectors for the disease since they do not suffer noticeably from the presence of the Plasmodium 
parasites and because they live for the 10 to 18 days required for the Plasmodium parasite to 
move through its sporogenic cycle from gametocyte to sporozoite[12]. Malaria has also been 
shown to be transmitted via human to human blood transfusions although little research has 
been done regarding the extent to which this occurs given the fact that most cases occur in 
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resource poor countries where screening is not feasible due resource limitations or the strain it 
would put on blood supply[13]. Transmission is also possible from mother to child during 
pregnancy, although most cases are asymptomatic[14]. 
Pathogenesis and Symptoms 
Malaria infection occurs in two phases referred to as the exoerythrocytic phase and the 
erythrocytic phase. The exoerythrocytic phase is typified by hepatic involvement, whereas the 
erythrocytic phase, as the name suggests, involves red blood cells. After infection via mosquito 
vector, the sporozoites present in the mosquito’s saliva migrate through the blood stream and 
take up residence in the hepatocytes of the liver. Here they undergo asexual reproduction. During 
this period of multiplication, no symptoms are generally experienced in the host. The sporozoites 
then may undergo a period of dormancy in the liver after which time they differentiate to yield 
thousands of merozoites[15]. These merozoites then cause the host hepatocytes to rupture while 
simultaneously wrapping themselves in ruptured hepatocyte cell membrane allowing them to 
avoid immune detection[16]. Some P. vivax, and possibly P. ovale, sporozoites do not 
immediately differentiate into merozoites, but instead into hypnozoites which can remain 
dormant for months to years before reactivating into merozoites leading to extended incubation 
and relapse in some cases caused by these species[17]. Once in the blood stream merozoites 
infect erythrocytes and begin the erythrocytic phase of the malaria life-cycle[15]. 
While in the red blood cells (RBCs), the parasites reproduce asexually and break off to 
invade other RBCs. This occurs in periodic waves resulting in clinical presentation of fevers which 
increase and decrease in severity corresponding with the release of merozoites into the blood 
stream[15]. Most merozoites do not differentiate while in the blood stream, but some exit the 
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erythrocytic phase by differentiating into male and female gametocytes. These gametocytes 
enable the parasite to move back to the mosquito vector where they can reproduce sexually, 
effectively restarting their lifecycle[11]. 
Malaria generally presents itself 8-25 days post-infection. Symptoms can present later, 
however, in patients who have taken prophylactic antimalarial medication[18]. Common 
symptoms include fever, shivering, arthralgia, vomiting, anemia, jaundice, hemoglobinuria, 
retinal damage, and convulsions[19]. The classic malaria symptom is sudden coldness followed 
by rigor and then fever which comes and goes in cycles two to three days in length. Severe malaria 
is usually the result of P. falciparum infection and presents 6-14 days after initial infection and 
may present with enlarged liver and spleen, severe headaches, cerebral ischemia, hypoglycemia, 
hemoglobinuria, and kidney failure[20]. 
Diagnostic Methods 
Summary 
The most proven method used in the diagnosis of malaria is microscopic examination of 
blood samples. Urine and saliva have also used as possible alternative specimen sources, but the 
viral load is lower in these fluids, therefore the same sensitivity levels can generally not be 
reached[21]. Additionally, techniques using antigenic and PCR amplification methods have been 
developed, but have not been widely implemented in regions with endemic malaria due to lack 
of equipment and high costs[22, 23]. In fact, many areas where malaria is prevalent cannot afford 
the laboratory equipment needed for microscopy and therefore rely on symptoms alone in the 
absence of definitive laboratory verification.  
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Microscopy 
As mentioned previously, microscopy of blood samples is the most proven and widely 
used method of definitive diagnosis. Through the microscopic examination of blood films, not 
only can the presence of malaria be established, but also the specific infective species. Thin film 
microscopy (and Figure 3 [24] Figure 2 [25] for the two most common malaria parasites) allows 
for the identification of the particular species since the parasite’s appearance is most obvious in 
this preparation. Thick film microscopy allows for a more sensitive investigation of the sample 
making it possible to identify infection at lower parasite levels. Generally, both methods are used 
in conjunction with one another to arrive at a definitive diagnosis[26]. While using both 
techniques in conjunction does result in effective differentiation between the various malaria 
causing species, more advanced methods are important since species determination cannot 
always be established via microscopy until the disease has had time to progress. This is especially 
true of P. knowlesi and P. malariae, both of which look nearly identical in the early stages of the 
disease but have different levels of severity in the host. P. malariae presents in a much more 
severe form than P. knowlesi so advanced diagnostic methods are required for early stage species 
identification in order to allow for optimal patient outcomes[27]. 
Figure 2: Photomicrograph of HPF containing Giemsa 
stained gametocytes of the P. falciparum parasite 
Figure 3: Photomicrograph of HPF containing Giemsa 
stained P. vivax trophozoite  
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Advanced Diagnostics (Antigen Tests and PCR) 
Antigenic malaria tests are relatively common and are useful in areas where the more 
standard microscopy tests are logistically not feasible. The most common antigen used is the P. 
falciparum lactate dehydrogenase (pLDH) antigen. This is the last enzyme in the parasite’s 
glycolytic pathway and also one of the enzymes which is produced in the highest quantities[28]. 
Additionally, this enzyme is rapidly cleared from the host’s blood after successful treatment 
allowing it to be used as an effective indicator that treatment has been a success. pLDH is also 
very similar amongst the various malaria species meaning that an antigenic detection system 
designed specifically for the most common and dangerous P. falciparum species is also effective 
at detecting other species [29, 30]. Antigen test kits for this enzyme are available commercially 
and only require a drop of blood and 15-20 minutes of processing time to present results as easily 
readable visual cues [31]. The downside of these tests, and antigenic tests in general is that their 
stated limit of detection is in the 200 parasites/μL range as opposed to the 5-20 parasites/μL 
range for by thick film microscopy [26, 32, 33]. Rapid real-time assays are currently being 
developed which utilize PCR and other molecular methods with the aim of being more accurate 
than microscopy. These methods, however currently require specialized lab equipment and 
therefore are more expensive and often not easily translated to field usage in endemic areas. 
Therefore, there is a major need for more sensitive diagnostic techniques that can be used in the 
field to detect low levels of parasitemia [34]. 
Treatment and Prognosis 
Over the last decade malaria parasites have developed resistance to the historical 
standard of care medication, chloroquine[35]. This has necessitated the use of a new class of 
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artemisinin-based combination therapies, (ACT) which have been shown to be effective against 
chloroquine resistant strains[36]. However, the high cost of the newer anti-malarial drugs has 
placed an enormous economic burden on the low-income countries of Sub-Saharan Africa with 
as much as 40% of healthcare spending attributed to fighting malarial infections [37]. 
Compounding this problem is the fact that far more cases of Malaria are treated than are 
definitively diagnosed. The WHO estimates that of patients tested for malaria, less than 50% were 
found to have the disease, leading to the conclusion that if testing were fully implemented, the 
ratio of diagnostic tests to ACTs would be ≥2 while in fact, the ratio is approximately 1:1[38]. This 
means that nearly half of expensive malaria treatment regimens are being used on patients 
without malaria creating a large and wholly unneeded economic burden on endemic nations. 
Compounding the public health concern is the fact that while febrile patients without malaria are 
being treated with ACTs, they are going untreated for their actual illness. 
Malaria exists at pandemic proportions in the tropical climates that are most conducive 
to mosquito infestations. Wealthier nations have successfully eradicated malaria by deploying 
mosquito containment strategies combined with effective anti-malarial therapies. However, 
lower-income and less advanced countries incapable of such prophylactic measures remain 
highly vulnerable to the disease. Moreover, the economic burden imparted on highly infected 
regions represents a positive feedback mechanism in which therapeutic costs absorb the scarce 
capital resources that could otherwise be used for preventative measures. A low-cost, early, and 
accurate diagnosis is an essential component of an effective anti-malaria campaign.   
The complex parasite life cycle creates a challenge for both diagnosis and therapy. As the 
parasite progresses between development stages, the antigen expression profile also changes. 
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Therefore, available biomarkers used by diagnostic or therapeutic approaches are also life cycle 
stage dependent. At the sporozoite stage, the parasite coat consists mainly of circumsporozoite 
protein (CS) [39]. Red blood cells infected with merozoites express merozoite surface antigen, 
MSA-1 and MSA-2, in addition to ring-infected erythrocyte surface antigen, RESA [40]. A 
biomarker commonly used in diagnostic assays is histidine-rich protein, a soluble protein 
secreted by merozoites. The protein is secreted only by P. falciparum and is known as pfHRPII. 
Merozoites secrete pfHRPII at detectable levels within 2-8 hours of infection with large amounts 
being released during RBC rupture [41].  
The development of improved diagnostic methods is currently one of the foundational 
principles of the Bill and Melinda Gates Foundation’s strategy to eradicate malaria by 2025. They 
state that “the majority of malaria infections occur in asymptomatic people, who are a source of 
continued transmission. A successful and accelerated eradication effort will target asymptomatic 
infections through community based efforts” [42]. The work contained in this thesis aims to take 
the first step towards the development of a novel malaria diagnostic which through its simplicity 
can easily be rolled out within malaria infected communities. This strategy hinges on improved 
diagnostics which can identify asymptomatic carriers of malaria. Since these asymptomatic 
individuals generally have low parasetemia levels, new approaches such as the one discussed 
herein are needed to effectively identify them and limit their transmission potential. 
Low-Resource Diagnostics 
Diagnostic devices, from simple to complex are an integral part of medical care and as 
such are required to enable effective treatment in rural and undeveloped environments as much 
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as they are in the developed world. Developing diagnostic tests for common endemic infections, 
such as malaria, tuberculosis, and human immunodeficiency virus can therefore have a major 
impact. The challenge is that while there are many effective diagnostic tests available which are 
compatible with modern healthcare infrastructure, low-resource settings present marked 
engineering challenges which are not present when engineering devices for use in non-resource 
constrained settings. In resource-constrained settings, low-cost and simplicity of operation come 
to the forefront as main design drivers. As such, the ideal diagnostic device for resource 
constrained POC settings would rely on an underlying physical phenomenon, deriving the driving 
force for the assay not from external power, but from the fundamental physics which drive the 
phenomenon in question. 
Early diagnosis is in some ways even more important in resource-constrained 
environments than in resource rich areas since limited medical resources lead to deficiency in 
treatment even upon diagnosis. This situation is compounded by the fact that treatments are 
generally not curative, but symptomatic, and diagnoses are based on more on general symptoms 
and indigenous disease burden rather than definitive diagnostic tests. 
This lack of effective early diagnosis, coupled with ineffective treatments shifts the 
balance of mortality causes from chronic diseases in developed nations to infectious diseases in 
developing nations. Additionally, delayed diagnosis allows infectious diseases to spread before 
rendered non-communicable via treatment making pathogens difficult to contain. Lastly, lack of 
effective diagnostic tests can lead to erroneous diagnoses which may lead to erroneous 
treatment and eventually to the development of drug resistant pathogens. While drug resistance 
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can be attacked through the development of new drugs, the cost of new drugs in often a difficult 
burden for the economy of developing countries to bear. [43] 
To combat these issues, it is extremely important to develop effective POC diagnostics 
which can be utilized effectively in rural areas as well as to take the burden off of modern testing 
facilities in urban centers. These POC diagnostics must be effective in environments with limited 
medical infrastructure such as facilities, instrumentation, or trained personnel and must be able 
to withstand storage in harsh conditions outside of climate controlled environments. 
Currently, RDTs are utilized in these regions. While these tests are easy to use and have 
been shown to have a limit of detection of approximately 100 parasites per μL [44, 45] operate 
with 95.4% sensitivity and 95.9% specificity  in a hospital setting[46], they can be inconsistent in 
their ability to detect malaria, when subjected to the harsh environmental conditions present in 
many of malaria endemic regions[43].  As such, there is a definite need to develop methods for 
improvement of these assays in the early detection of malaria. As an example, the gold standard 
for malaria diagnosis is thick or thin film microscopy which can detect parasetemia as low as 5 
parasites/µL. [47] This test, however, must be performed by trained personnel in a controlled 
laboratory and therefore is not feasible at the POC in most malaria-endemic areas. 
Immunochromatographic RDTs on the other hand, are used in these settings because they do 
not require training nor facilities. These RDTs consist of a paper-based substrate through which 
sample fluid flows by capillary action. If the parasite biomarker, commonly Plasmodium 
falciparum histidine rich protein II (pfHRPII), is present, it binds to a label within the strip which 
is then immobilized by a secondary antibody, forming a visible line as the sample moves down 
the strip. This technology has a limit of detection of 100 parasites/µL, far above that of the gold 
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standard [48]. While sensitivity for samples with 500-1000 parasites/µL is relatively high at 92.6%, 
this drops off to 89.3% for 100-500 parasites/µL and 53.9% for 0-100 parasites/µL, well below 
WHO recommended sensitivity of 95% at 200 parasites/µL [49]. In addition to these functional 
limitations, since RDTs rely on antibodies to function properly, they must be stored within a 
relatively narrow temperature range of 1-40°C [49]. 
Problem 
 Lateral flow strips need to be made more sensitive, that is, they need to detect parasites 
at lower concentrations within patient samples. Since parasites are essentially evenly distributed 
in blood, increases in blood volume result in an increase in absolute parasites for detection. Using 
currently available RDTs, approximately 5µL is used, although there is no strict maximum, much 
more than this would not be able to be used due to physical constraints of the assays. 
Additionally, increasing the sample volume leads to increased red blood cells which can block 
capillary action within the lateral flow strip or can make the test simply show up as red. In order 
to solve this problem, we need to increase the amount of what we want (parasites) while 
decreasing the amount of what we don’t want (red blood cells and other cellular components). 
In order to do this, we are designing a biomarker concentration process which allows to take a 
larger volume of patient sample and then extract the portion of the sample which we want while 
reducing the presence of background material. 
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Biomarker Concentration Design 
In order to address the aforementioned issues with current RDTs—cost, ease-of-use, and 
performance—we are working towards developing a method by which biomarkers in malaria 
infected patient samples can be concentrated to lead to more robust diagnosis. The proposed 
method utilizes 1µm diameter magnetic beads which are surface-functionalized with Cobalt 
nitrilotriacetic acid (CoNTA). CoNTA serves to bind to the 51 histidine residues on histidine rich 
protein two (HRPII), a biomarker of P. falciparum. In our proposed design, a patient sample is 
mixed with the particle solution, allowing for HRPII to bind to suspended CoNTA. The solution is 
then loaded into a small diameter tube an RTD and a neodymium magnet (Figure 4). The force 
exerted by the magnetic field on the ferromagnetic micro-particles pulls the beads onto the RTD 
(Figure 4) which is then eluted with imidazole to release the HRPII from the beads (Figure 5).  
Magnet 
RDT 
Magnetic Beads 
Patient Sample 
Figure 4: Patientsample loading - A patient sample is loaded into a piece of small diameter tubing with 
one end sealed off. Tubing is placed above the sample window of the RDT at a and magnetic beads are 
allowed to settle to the pendant miniscus at the bottom of the tube. 
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Magnet 
RDT 
Figure 6: Sample transfer - The tube containing magnetic micro-particles and the patient sample is 
moved slightly closer to the RDT until the force from the magnet pulls the magnetic particles through 
the sample miniscus allowing the micro-particles and their captured biomarkers to transfer to the sample 
window. 
Figure 5: Particle elution - The transferred micro-particles are eluted with imidizole, releasing the HRPII 
biomarker from the beads, allowing them to flow in solution down the lateral flow strip and trigger a 
positive result. 
Magnet 
RDT 
Imidazole Positive Results 
Eluted Beads 
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This approach helps to deal with the limited sample volumes in the 5-10 µL range [50]  
which can be loaded onto an RTD by concentrating a large patient sample, removing a substantial 
portion of the HRPII from the solution and delivering it directly to the RTD. It allows for accurate 
testing at lower levels of parasetemia than current methods since at a given level of parasetemia, 
we can deliver more biomarker to the sample window while also transferring fewer blood cells. 
We aim to elucidate design considerations such as tubing angle and micro-particle mass which 
result in the highest efficiency fluid and particle transfer while meeting the constraint that 
particles must jump from the tube meniscus to the surface at a distance compatible with off-the-
shelf RDTs (≥4mm).  
This proposed HRPII amplification method is simple to use, inexpensive to manufacture, 
stable at a wide range of environmental conditions, and enhances the diagnostic ability of 
inexpensive and widely available lateral flow assays. Furthermore, this method has the ability to 
be used as a general purpose method for concentration and transfer of small concentrated 
volumes of any fluid which can be attached to surface functionalized magnetic beads. 
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CHAPTER II 
DEVELOPMENT OF A MAGNETIC BEAD BASED FLUID TRANSFER SYSTEM 
Introduction 
By suspending a tube containing magnetic micro particles in solution, within a magnetic 
gradient field, we can selectively transfer particles out of a fluid and to the magnet’s surface. In 
this experiment we developed a proof-of-concept system in which suspended beads can be 
transferred over a vertical distance of approximately 8mm from the surface of a strong 
neodymium magnet. The bead transfer distance is generally proportional to bead mass in the 
tube, reaching a maximum at bead masses above 800µg for a tube held with the open end parallel 
to the magnet’s surface and for masses above 400µg for a tube held 45° to the magnet’s surface. 
We additionally found that beads transferred from a flat tube at a mass independent efficiency 
of approximately 55% whereas when transferred from an angled tube, there is a dependence 
between total bead mass and transfer efficiency. Lastly, we found that small amounts of fluid can 
be successfully transferred along with the micro-particles and that the fluid amount per unit mass 
of micro-particles trends higher when using an angled tube. 
These findings serve as a basis for understanding the physical phenomena present and 
the parameter space available as we move toward the development of a low resource malaria 
biomarker concentration design. 
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Hypothesis 
Our hypothesis is that using magnetic beads contained within a tube, we can concentrate 
and transfer fluid and magnetic beads across a gap by using a strong magnetic field to allow the 
beads to overcome surface tension at the air-fluid interface of a suspended tube. We also 
hypothesize that simple optimization of fluid and bead transfer can be accomplished by changing 
the angle of sample tube with respect to the magnet due to the changes in surface tension forces 
resulting from the angular change. In this experiment, fluid is transferred both as entrapped fluid 
within a bulk bead mass and as fluid attached to beads.  
Introduction 
The use broadly accepted use of point of care (POC) diagnostics has greatly changed diagnostic 
approaches in areas with high levels of infectious diseases for the better[51]. These nations with 
high incidence of infectious disease present a challenging environment for diagnosis of diseases, 
often characterized by poverty, intermittent electricity, hot and humid conditions, and a lack of 
skilled medical personnel. Traditional methods of disease detection which are commonly used in 
developed areas such as enzyme immunoassays (ELISA) and quantitative polymerase chain 
reaction (qPCR) are rarely useful in such areas due to environmental conditions which affect 
reagent stability and the aforementioned lack of personnel at the point of care to carry out 
testing [52]. The gold standard for detection of blood-borne pathogens, light microscopy is 
compatible with hot and humid environments, yet the lack of qualified personnel to carry out 
testing also limits its usefulness in many areas with high indigenous burden of infectious disease. 
In an effort to address the shortcomings of traditional diagnostic methods, lateral flow 
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immunochromatographic rapid diagnostic tests (RDTs) were developed [48, 53]. These tests can 
be easily used by untrained personnel, but they come with their own set of shortcomings. These 
inexpensive tests which deliver rapid results and are easy to use and interpret, have been widely 
used in public health programs in order to aid with patient management, disease surveillance, 
and treatment campaigns[54, 55]. In fact, in 2013 over 160 million malaria RDTs were distributed 
by national malaria control programs [43]. These RDTs detect protein biomarkers of the malaria 
parasite. As it is the most common malaria variant, most RDTs detect Histidine Rich Protein II 
(pfHRPII) which is indicative of Plasmodium falciparum, however some RDTs detect Plasmodium 
lactate dehydrogenase (pLDH) which serves as a pan-specific biomarker.[53] 
Although the use of such tests has made an overwhelmingly positive impact on the 
detection of malaria in developing countries, their widespread use has highlighted the need for 
improved tests. Specifically, tests are needed which are able to detect low levels of malaria 
biomarker. The WHO periodically reviews the landscape of available RDTs and sets guidelines for 
their performance. Most recently, the WHO has specified a limit of detection for these tests at 
200 parasites/µL of blood. [49] This limit of detection is sufficient for diagnosis of symptomatic 
malaria infection, however, a lower limit of detection is needed in order to identify many 
asymptomatic patients who serve as transmission reservoirs for malaria. In order to identify 
these patients, lower limits of detection are needed. Exacerbating this issue is the fact that poor 
manufacturing standards and storage conditions render many RDTs unreliable or unusable even 
when held to the current limit of detection guideline. [56]  
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Methods 
Standard Curve Determination 
FITC 
A standard curve relating FITC concentration to fluorescence was prepared on the nanodrop 
machine by diluting stock 1.15mM FITC solution to the following concentrations: 575µM, 460µM, 
345µM, 115µM, 57.5µM, 23µM, 11.5µM, 8.6µM, 5.8µM, 2.9µM, 1.15µM, 863nM, 575nM, 
288nM, and 115nM. Nine 2µL aliquots were taken from each of these samples and their 
fluorescence was measured on a Nanodrop spectrofluorometer (S/N FL014, Thermo Fisher 
Scientific Waltham, MA) at an excitation wavelength of 495nm and an emission wavelength of 
519nm. The mean fluorescence value was then used to construct a standard curve. 
Beads 
A standard curve relating bead concentration to absorbance at 700nm was prepared on the 
nanodrop machine by diluting a known mass of beads (0-400µg) with 100µL DI water. Three 2µL 
aliquots of these beads were then individually loaded onto a Nanodrop ND-1000 
spectrophotometer (S/N 2749, Thermo Fisher Scientific, Waltham, MA) and absorbance 
measured to establish a relationship between bead concentration and measured absorbance.  
Sample Preparation 
Fluorophore Loading 
Fluorinated ethylene propylene (FEP) tubes were cut to a length of 25mm using a custom made 
miter box and a razor blade in order to assure that the cut ends of the tube were straight so as 
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to not affect surface tension due to geometric variation. These tubes were then capped on one 
end using sealing wax. Approximately 30µL of fluorophore solution (1.15mM FITC stock solution, 
0.1mg/mL GPF, or 0.0065mg/mL Poly-L-his-FITC) was loaded into the other end of the tube by 
placing a 50µL pipette tip into the end as deep as possible and slowly withdrawing the tip 
throughout loading to allow air to escape.  
Bead Dilution and loading 
Determined bead masses were loaded into Eppendorf tubes and diluted using water to a volume 
of approximately 10µL. These beads were then loaded into the FITC filled tubes. Loading was 
performed by attaching the FITC tube to the side of a ¾” cube N45 Neodymium magnet with the 
top of the tube slightly above the magnet’s edge. Bead solution was then loaded into a 10µL 
pipette and the tip of the pipette was introduced into the FTIC meniscus. The magnetic field then 
caused the beads to transfer from the pipette tip into the FITC tube. The pipette was held in this 
position for 10 seconds after all visible beads had transferred into the tube in order to ensure 
complete bead transfer. 
Drop experiment 
Test Fixture 
A custom video fixture (Figure 7) was designed based on the test frame from a Rame-Hart Model 
200 goniometer (Rame-Hart Instrument Company, Netcong, NJ). The standard goniometer 
camera was replaced with an Edgertronic high speed camera (Edgertronic, San Jose, CA) with a 
60mm Nikkor AF 1:2.8D macro lens (Nikon Corporation, Tokyo, Japan). A custom adaptor was 
fabricated to allow for the dropper holder mechanism on the goniometer to instead hold the 
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aforementioned 1/8” ID tube at a pre-determined angle to the magnet’s North face. This part 
was fabricated on a ProJet 3510 3D Printer (3D Systems, Rock Hill, SC) and attached to the 
goniometer platform. Additionally, a second mounting bracket was fabricated using the ProJet 
printer which was designed to hold a cubic 3/4” N45 Neodymium magnet on the platform and 
oriented so that the North face was parallel to the ground. Light for the test system was provided 
using a lens-mounted Amscope LED-144 ring light (AmScope, Irvine, CA) and a Rame-Hart 115V 
Fiber Optic Illuminator Kit. This apparatus was used in order to image a 1/8” outer diameter tube 
and sample as the goniometer platform (w/mounted magnet) was raised toward the tubing using 
the goniometer platform’s integrated micrometer.  
 
Figure 7: Goniometer-based high-speed video test fixture 
 
High speed 
camera 
Fiber optic illuminator Amscope Light 
Micrometer Goniometer frame 
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Test Fixture Video Distance Calibration 
Distance between the high-speed camera and the test platform was locked into place at a 
distance of 20cm for all experiments in order to assure accurate distance calibration for image 
post-processing. In order to determine a calibration curve, a linear scale with resolution to 0.1mm 
was attached to the platform at the proximal edge of the magnet’s north face and a high speed 
video was recorded. A single frame from the video was extracted and loaded into ImageJ. Lines 
were then drawn between scale lines using ImageJ and the number of pixels in the line was 
related to the distance shown on the scale to determine mm/Pixel. This was repeated ten times 
for distances between 1.5 and 12.5mm and a line was fit to the data. 
Bead Transfer 
For testing, the platform holding the magnet was moved using the goniometer’s vertically 
oriented micrometer to its lowest position (furthest away from the test sample). The upper arm 
was then positioned such that the center of the dropper holder was positioned over the center 
of the outer edge of the magnet to allow for positioning of the sample in the area of the magnet 
with the highest magnetic field gradient. The magnet’s surface was then covered with a sheet of 
parafilm. After the magnet was covered with parafilm, the tube was loaded into the adaptor (flat 
or 45° depending on the experiment being run) and the adaptor was locked into place in the 
goniometer’s dropper holder. The micrometer was then turned by hand at approximately 1 
rotation per second (corresponding to approximately 1mm/sec vertical travel) to move the 
magnet upwards and towards the tube. After beads physically transferred from the tube to the 
surface of the magnet, the trigger on the high-speed camera was depressed, capturing video 
from the transfer of the beads to the magnets’ surface. The tube was then removed from the 
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holder and saved for processing and the parafilm was removed from the surface of the magnet 
with the transferred beads. 
Sample Analysis 
Transferred beads processing 
The transferred sample was washed off of the parafilm and into a 2mL Eppendorf tube using 
100µL of deionized water. The sample was then placed Promega 12 slot magnetic separator 
(Promega, Madison WI) for 2 minutes and the supernatant was collected in a separate 2mL 
Eppendorf tube. The remaining sample was then re-suspended and washed with 1000µL of 
deionized water three times using a magnetic separator to isolate the beads between wash steps. 
After the final wash step, beads were re-suspended in 100µL DI water and then three 2µL aliquots 
were individually loaded onto the nanodrop machine to measure absorbance. For higher 
concentration samples for which the absorbance exceeded the dynamic range of the nanodrop, 
samples were further diluted in order to allow for accurate absorbance readings. Absorbance 
was then converted to concentration and then to bead mass using the standard curve to 
determine the mass of beads transferred. 
Supernatant Processing 
Three 2µL aliquots were then taken from the supernatant and loaded individually onto the 
nanodrop machine and fluorescence was measured. A standard curve (see following standard 
curve section) was then used to calculate the amount of fluorophore transferred and then the 
total fluid transfer amount was calculated.  
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Left-Behind beads processing 
The polyethylene tube containing non-transferred beads and remaining fluorophore was cut with 
a razor blade and the contents diluted and emptied into a 2mL Eppendorf tube using 1000µL of 
DI water. This solution was then loaded onto a magnetic separator and the supernatant 
discarded. The beads were then re-suspended in 1000µL DI water and washed three times using 
the magnetic separator to isolate the beads between wash steps. The washed beads were then 
re-suspended in 100µL DI water and then three 2µL aliquots were loaded individually onto the 
nanodrop machine to measure absorbance. For higher concentration samples for which the 
absorbance exceeded the dynamic range of the nanodrop, samples were further diluted in order 
to allow for accurate absorbance readings. Absorbance was then converted to concentration and 
then to bead mass using the standard curve to determine mass of beads remaining in the tube. 
Bead Transfer Distance 
High speed videos were downloaded from the camera and loaded into Adobe Premiere and 
converted into a series of uncompressed TIFF images. The TIFF series was then loaded into imageJ 
and advanced to the frame where the transferred drop could be seen suspended in air between 
the polyethylene tube and the surface of the magnet. A line was drawn of the shortest distance 
between the tube edge and the corner of the magnet and the distance in pixels was recorded. 
This was done three times and the average distance in pixels was recorded. This distance was 
then converted to mm using the previously established calibration curve.  
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Results 
Standard curves and Calibration 
FITC 
The calibration curve for the spectrofluoremeter was determined to be: 
𝑅𝐹𝑈 = 5833.5𝑐 − 3467.6  
𝑅2 = 0.9859,  
𝑅𝐹𝑈 = 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒, 𝑐 = 𝐹𝐼𝑇𝐶 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑚𝑀 
Because of excessive variation in measurements at concentration above 50µM, the final standard 
curve only consisted of points at or below this threshold. Samples at concentrations above 50µM 
were diluted so that the resulting sample applied to the spectrofluoremeter was under 50µM. 
For example, a 160µM sample would be 4x diluted with deionized water and then a 2µL aliquot 
of this 40µM sample would be measured on the spectrofluoremeter. The resulting fluorescence 
reading was then be multiplied by the dilution factor to represent the fluorescence at the correct 
sample concentration. 
Beads 
The calibration curve for the spectrophotometer was: 
𝐴 = 0.0023𝑚 − 0.0026  
𝑅2 = 0.956  
𝐴 = 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑖𝑛 𝐴𝑈, 𝑚 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠
100𝑢𝐿
𝑖𝑛 𝜇𝑔 
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Based on limitations to the dynamic range of the ND-1000 spectrophotometer, concentrations 
above 100µg/100µL of solution were discarded, limiting the range of the standard curve to 0-
100µg of beads in 100µL of solution. The minimum measurable bead mass was calculated to be 
25.2µg of beads per 100µL of solution. The upper limit of absorbance was approximately 250AU. 
In order to test samples which at concentrations above 25µg/100µL, samples were re-suspended 
and then diluted into the <25µg/100µL range using the same process as was used on the 
fluorescence samples. 
Linear scale calibration 
Based on the aforementioned calibration protocol images captured with the high-speed camera 
a calibration curve was relating distance to pixels using the following equations. This curve was 
valid for the test fixture parameters explained in the test fixture video calibration section. 
𝑑 = 20.691𝑝, 𝑅2 = 0.9999 
𝑑 = 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑖𝑛 𝑚𝑚, 𝑝 = 𝑝𝑖𝑥𝑒𝑙𝑠  
Fluid Transfer 
We determined that using the aforementioned bead transfer protocol, we were able to 
reliably transfer approximately 1.2nL of fluid per microgram of beads. The relationship between 
fluid transfer and bead volume had a linear relationship for tubes openings parallel and 45° to 
the magnet surface with R2 values of 0.8779 and 0.9471 respectively. This trend was seen over 
the entire tested range from 100µg to 1600µg and there was no significant difference between 
the parallel and 45° samples at any of the tested concentrations (Figure 8).  
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Figure 8: Transferred Fluid volume vs. Loaded bead mass - There was a positive linear relationship between initial bead volume 
and the amount of fluid transferred with the beads and no significant difference between the two sample types. Sample with 
tube parallel to magnet’s face shown in black and tube 45° to magnet’s face shown in white. 
 
Variability, expressed as standard deviation at each initial bead mass as a percentage of 
the mean, was consistent across all samples within each sample set. However, 45° samples 
showed significantly less variability as compared to parallel samples when comparing standard 
deviations of the two groups using a Student’s t-test (p < 0.0004) (Figure 9). 
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Figure 9: Fluid transfer variability - Variability amount of fluid transferred was significantly higher (p<0.001) for the samples 
parallel to the magnet’s face. Variability as a percent of the mean remained constant with respect to concentration across both 
sample sets. Sample with tube parallel to magnet’s face show in black and tube 45° to magnet’s face shown in white. Sample with 
tube parallel to magnet’s face shown in black and tube 45° to magnet’s face shown in white. 
 
On a bead mass basis, the amount of fluid transferred exhibits an overall negative linear 
relationship for samples where the tube was held parallel to the magnet. However, for those 
samples held at a 45° angle there was a positive linear trend up to and including the 400µg sample 
however, the only significant difference was found for the 200µg sample where more fluid was 
transferred per µg of beads for the parallel sample as opposed to the 45° sample (p = 0.006). At 
concentrations higher than 400µg, the amount of fluid transferred per microgram, showed 
similar trends for both 45° samples and parallel samples (Figure 10). 
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Figure 10: Fluid transfer efficiency in nL of fluid per µg of beads - At loaded bead masses above 600µg the 45° and parallel sample 
sets showed similar trends of a slightly decreasing efficiency on a per bead mass basis as loaded bead mass increased. There was 
a marked positive trend, however for the 45° samples at concentrations between 100µg and 400µg, reaching an efficiency peak 
of 2.72nL/ µg at an initial bead load of 400µg. Sample with tube parallel to magnet’s face shown in black and tube 45° to magnet’s 
face shown in white. 
Bead Transfer distance 
Bead transfer distance increased linearly with increasing bead mass up to 800µg, after which it 
approximately leveled off at approximately 8mm. This trend was similar for both parallel and 45° 
configurations (Figure 11). The 45° configuration had generally higher transfer differences over 
the lower end of the bead mass spectrum with significantly higher transfer distance at 300µg 
bead mass (p = 0.019) and nearly significantly higher transfer distance at 200µg (p = 0.064) and 
400µg (p = 0.062) respectively.  
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Figure 11: Bead Transfer Distance - Both samples sets showed similar transfer distances. Distance increased with initial bead 
mass, but began to level off around a bead mass of 800µg and at a distance of approximately 8mm. Sample with tube parallel to 
magnet’s face shown in black and tube 45° to magnet’s face shown in white.  
Transferred bead mass 
Bead mass transfer increased with increasing concentration as expected. While the parallel 
configuration showed generally consistent transfer efficiencies (amount of loaded beads 
transferred) the 45° configuration showed increases in efficiency up to 800µg and then 
decreasing efficiency at higher concentrations. The parallel samples showed a third order 
relationship with respect to concentration. The same data normalized by initial bead mass to 
compute transfer efficiency can be seen in Figure 13. 
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Figure 12: Transferred bead mass - As shown above, samples at 45° to tube showed a different trend with respect to increasing 
bead mass than those parallel to the tube, exhibiting higher bead transfer between 600µg and 1000µg of bead mass (p <. 005). 
At most of the lower and higher concentrations, the parallel tube showed higher bead mass transfer. (100µg, 300µg, 1400µg, 
p<.05). Sample with tube parallel to magnet’s face shown in black and tube 45° to magnet’s face shown in white. 
 
Figure 13: Bead Transfer Efficiency: Percentage of initially loaded beads transferring from the tube to the magnet shows that the 
45° configuration more efficiently transfers beads through the middle of the tested range of bead masses and less efficiently at 
the ends of the range. Parallel samples, however, perform similarly efficiently throughout the mass range. Samples with tube 
parallel to magnet’s face shown in black and tube 45° to magnet’s face shown in white. 
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Discussion 
A strong magnetic field can be used as a driving force to transfer magnetic beads out of a 
solution against surface tension and across a gap whose magnitude depends on the mass of 
beads used. The test sample is loaded into a capillary tube and as such can be suspended in a 
manner in which the surface tension forces present at the pendant meniscus are higher than 
those exerted by gravity. As the tube is moved closer to the magnet’s surface, the magnetic 
gradient and corresponding magnetic force increases until it reaches a point at which the sum of 
gravitational force and the magnetic force exceed surface tension forces and magnetic particles 
contained within the tube transfer to the surface of the magnet.   
We saw that an increase in bead transfer efficiency coincides with a slight increase in 
transfer distance suggesting that higher transfer distances can be obtained by ensuring that the 
bulk bead mass stays intact. This most likely occurs because having a larger cohesive bead mass 
means that a larger diameter body is effectively being pulled through the pendant meniscus, 
allowing the particles within the mass to be subject to a lower surface tension as a group than 
they would individually. This means that less magnetic force is required to pull them through the 
liquid-air interface, therefore allowing them to transfer at a higher distance from the magnet. 
This finding was also consistent with a visual investigation of the captured video frames and was 
especially pronounce for 45° samples (Figure 14). Generally, the 45° bead masses split before 
transferring at lower concentrations, stayed intact through the middle mass range and split at 
the higher mass range. The parallel samples, however, tended to behave consistently across the 
entire range of bead masses tested (Figure 13). The ability of the 45° samples to stay intact as a 
mass of beads at higher bead loads and their tendency to be split by the edge of the tube at lower 
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bead loads most likely contributed to the correlation between transfer distance and transfer 
efficiency.  
 
Figure 14: Transfer efficiency seems to be indicative of higher transfer distances - Beads seem to be transferred more 
efficiently at higher transfer distances than at lower transfer distances. This seems to be especially true for the 45° samples. 
Samples with tube parallel to magnet’s face shown in black and tube 45° to magnet’s face shown in white. 
In contrast, we generally see that greater fluid transfer occurs in sample in which the 
overall transfer efficiency is not as high (Figure 15). This makes intuitive sense since fluid transfer 
occurs through fluid adhering to the surface of beads. More disperse beads, therefore allow for 
more fluid to transfer while not transferring as much of the bulk bead mass. This trend is more 
evident with the parallel samples than with the angled samples, most likely due to extra variables 
introduced into the system through the orientation of the tube. 
Cohesive forces between the magnetic particles allow for a bulk mass of magnetic 
particles to transfer across the gap to the magnet while some beads separate from the bulk and 
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remain in the fluid. Based on the data we gathered, we found no relationship over the tested 
range with respect to the percentage of beads which remain with the bulk bead mass and which 
remain behind when the surface of the tube is held parallel to the magnet. However, when the 
surface of the tube is held at a 45° angle with respect to the magnet’s surface cohesive bulk 
transfer tends to occur to a greater extend at bead masses between 400µg and 1000µg. Our 
hypothesis is that having the tube angled biases the end of the tube to allow for bubble exchange. 
This allows air to slip through one side of the tube above the beat mass and overcome the internal 
vacuum created as gravity and magnetism force beads (and fluid) out of the end of a sealed tube. 
In the parallel samples, there is no bias for bubble exchange and therefore, beads are pulled out 
until a critical amount is able to overcome the surface tension and be pulled through the 
meniscus to the magnet. For angled samples, this does not need to happen since when the 
bubble exchange occurs the magnetic particles and the surrounding fluid are released from the 
tube. This effect is especially pronounced in the 600µg to 1000µg range. Above this, the angled 
samples have such a large bead mass that they behave much like the parallel samples and below 
this, there is so little bead mass, that when the bubble exchange occurs, it tends to happen very 
quickly, redistributing the small mass and only forcing out a small portion. 
Also of note is that prior to bead transfer most of the beads had settled to the air/fluid 
interface, however the timing for settling was not standardized introducing additional error into 
the system. Even more importantly, for the 45° samples, there were many instances in which 
there was incomplete bead transfer, likely contributing to the increased variability present in 
these samples. In some instances, the bead mass would separate and only a partial portion of 
the bead mass would transfer. 
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Figure 15: Effect of transfer efficiency on total fluid transfer - As shown above, there is a generally decreasing trend when 
comparing fluid transfer with transfer efficiency. Samples with tube parallel to magnet’s face shown in black and tube 45° to 
magnet’s face shown in white. 
Future Directions 
While we only looked at a single type of particle and tube type, while doing a simple 
experiment with tube angle, the problem of bead transfer by a magnetic field has many 
parameters which could influence experimental outcomes. Some of these variables include 
tubing shape, particle type, particle shape, magnet strength, magnet shape, fluid viscosity, and 
surface tension. All of these properties should be examined in more detail in order to optimize 
the design set forth in this paper. As a first step, future research should aim to understand the 
effect of the individual parameters mentioned on outcomes such as bead transfer distance, bead 
transfer efficiency, and fluid transfer efficiency. Further research needs to be done with respect 
to different bead types and how they alter the transfer of both beads and fluid across a gap. 
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Additionally, the effects of different magnetic fields and varying magnetic fields need to be 
further investigated in order to fully optimize the model set forth in this thesis. Other interesting 
and useful aims would include investigation of how this model performs in various fluids, 
especially those biological in nature such as blood or urine since with functionalized beads, this 
method could serve as an effective low resource method for concentrating and transferring 
biomarkers from native biological media to various commercial rapid diagnostic tests. 
 A second step in this design process is the determination of the ability of the beads to 
concentrate an HRPII analogue, poly-l-histidine (PLH), and aggregate to be transferred out of the 
sample tube and onto a surface. This jump distance is important since in order for the method to 
be effective, the magnetic field must be strong enough to attract the bead mass through the 
thickness of the RDT and overcome the surface tension in the sample tube. 
 This method has potential for use in any scenario in which small volumes of fluid need to 
be transferred reliably and repeatedly in conjunction with functionalized magnetic particles. A 
prime example of this is in rapid diagnostic tests utilized for malaria diagnosis. 
Once the individual affects are understood, the experiments should be extended beyond 
the highly idealized system presented here using water as the fluid medium. The use of blood in 
place of water in this experiment would add many difficulties in that one would have to worry 
about the effects of increased viscosity on settling time as well as the interactions of red blood 
cells with suspended micro-particles and whether the presence of these cells impeded particle 
aggregation at the fluid air interface.  
 
 40 
 
REFERENCES 
1. Martin, S.K., et al., Unified Parasite Lactate Dehydrogenase and Histidine-Rich Protein 
ELISA for Quantification of Plasmodium falciparum. American Journal of Tropical 
Medicine and Hygiene, 2009. 80(4): p. 516-522. 
2. Kifude, C.M., et al., Enzyme-linked immunosorbent assay for detection of Plasmodium 
falciparum histidine-rich protein 2 in blood, plasma, and serum. Clin Vaccine Immunol, 
2008. 15(6): p. 1012-8. 
3. Dondorp, A.M., et al., Estimation of the total parasite biomass in acute falciparum malaria 
from plasma PfHRP2. PLoS Med, 2005. 2(8): p. e204. 
4. WHO, F., CDC, TDR, Malaria Rapid Diagnostic Test Performance. 2012. 
5. WHO, World Malaria Report, 2013. 
6. Mueller, I., P. Zimmerman, and J. Reeder, Plasmodium malariae and Plasmodium ovale--
the "bashful" malaria parasites. Trends in Parisitology, 2007. 23(6): p. 278-83. 
7. Collins, W., Plasmodium knowlesi: a malaria parasite of monkeys and humans. Annual 
Review of Entomology, 2012. 57: p. 107-21. 
8. Nadjim, B. and B. RH, Malaria: an update for physicians. Infectious Disease Clinics of North 
America, 2012. 26(2): p. 243-59. 
9. Day, K., R. Hayward, and M. Dyer, The biology of Plasmodium falciparum transmission 
stages. Parasitology, 1998. 116(S1): p. S95-S109. 
10. Talman, A., et al., Gametocytogenesis: the puberty of Plasmodium falciparum. Malaria 
Journal, 2004. 3: p. 24. 
11. National Institute of Allergy and Infectios Diseases: Malaria. National Institute of Health, 
2012. 
12. Malaria: Anopheles Mosquitos, in Centers for Disease Control and Prevention2010. 
13. Owusu-Ofori, A., C. Parry, and I. Bates, Transfusion-transmitted malaria in countries 
where malaria is endemic: a review of the literature from sub-Saharan Africa. Clin Infect 
Dis, 2010. 51(10): p. 1192-8. 
14. Lesko, C., P. Arguin, and R. Newman, Congenital Malaria in the United States: 1966 to 
2005. Archives of Pediatrics & Adolescent Medicine, 2007. 161(11): p. 1062-7. 
15. Bledsoe, G., Malaria primer for clinicians in the United States. Southern Medical Journal, 
2005. 98(12): p. 1194-204. 
 41 
 
16. Vaughan, A., A. Aly, and S. Kappe, Malaria parasite pre-erythrocytic stage infection gliding 
and hiding. Cell Host Microbe, 2008. 4(3): p. 209-18. 
17. Richter, J., et al., What is the evidence for the existence of Plasmodium ovale hypnozoites. 
Parasitology Research, 2010. 107(6): p. 1285-90. 
18. Nadjim, B. and R. Behrens, Malaria: an update for physicians. Infectious Disease Clinics of 
North America, 2012. 26(2): p. 243-59. 
19. Beare, N., et al., Malarial retinopathy: a newly established diagnostic dign in severe 
malaria. American Journal of Tropical Medicine, 2006. 75(5): p. 790-7. 
20. Trampuz, A., et al., Clinical review: severe malaria. Critical Care, 2003. 7(4): p. 315-23. 
21. Sutherland, C. and H. R, Detecting malaria outside the blood. Journal of Infectious Disease, 
2009. 199(11): p. 1561-3. 
22. Ling, I., et al., Antibodies to the glutamate dehydrogenase of Plasmodium falciparum. 
Parasitology, 1986. 92(2): p. 313-24. 
23. Mens, P., et al., Detection and identification of human Plasmodium species with real-time 
quantitative nucleic acid sequence-based amplification. Malarial Journal, 2006. 5(80): p. 
80. 
24. S, G., This thin film Giemsa stained micrograph reveals a mature Plasmodium vivax 
trophozoite, 5863, Editor 1979, Centers for Disease Control and Prevention: 
http://phil.cdc.gov/phil/details.asp?pid=5863. 
25. M, M., Photomicrograph of a blood smear contains a macro- and microgametocyte of the 
Plasmodium falciparun parasite, in http://phil.cdc.gov/phil/details.asp?pid=2704, 2704, 
Editor 1973, Centers for Disease Control and Prevention. 
26. Wathurst, D. and J. Williams, Laboratory diagnosis of malaria. Journal of Clinical 
Pathology, 1996. 49(7): p. 533-8. 
27. McCutchan, T., R. Piper, and M. Makler, Ue of malaria rapid diagnostic test to identify 
Plasmodium knowlesi infection. Emerging Infectious Disease, 2008. 14(11): p. 1750-2. 
28. Vander Jagt, D., L. Hunsaker, and J. Heidrich, Partial purification and characterization of 
lactate dehydrogenase from Plasmodium falciparum. Molecular Biochemistry and 
Parasitology, 1981. 4(5): p. 255-64. 
29. Iqbal, J., et al., Persistent histidine-rich protein 2, parasite lactate dehydrogenase, and 
panmalarial antigen reactivitiy after clearance of Plasmodium falciparum monoinfection. 
Journal of Clinical Microbiology, 2004. 42(9): p. 4237-41. 
 42 
 
30. Brown, W., et al., Comparative structural analysis and kinetic properties of lactate 
dehydrogenases from the four species of human malarial parasites. Biochemistry, 2004. 
43(20): p. 6219-29. 
31. Pattanasin, S., et al., Evaluation of a new Plasmodium lactate dehydrogenase assay 
(OptiMAL-IT) for the detection of malaria. Transactions of the Royal Society of Tropical 
Medicine, 2003. 97(6): p. 672-4. 
32. Moody, A., Rapid diagnostic tests for malaria parasites. Clinical Microbiology Review, 
2002. 15(1): p. 66-78. 
33. Murray, C. and J. Benett, Rapid diagnosis of malaria. Interdisciplinary Perspectives of 
Infectious Disease, 2009. 
34. Redd, S., et al., Clinical algorithm for treatment of Plasmodium falciparum malaria in 
children. Lancet, 2006. 347(8996): p. 223-7. 
35. Bloland, P.B. Drug resistance in malaria. 2001; Available from: 
www.cdc.gov/malaria/pdf/bloland_WHO2001.pdf. 
36. Nosten, F. and P. Brasseur, Combination therapy for malaria: the way forward? Drugs, 
2002. 62(9): p. 1315-29. 
37. WHO World Malaria Report. 2008. 
38. WHO, World Malaria Report 2012, 2012, World Health Organization. p. 195. 
39. Plassmeyer, M.L., et al., Structure of the Plasmodium falciparum circumsporozoite protein, 
a leading malaria vaccine candidate. J Biol Chem, 2009. 284(39): p. 26951-63. 
40. Perlmann, H., et al., Antibodies in malarial sera to parasite antigens in the membrane of 
erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med, 
1984. 159(6): p. 1686-704. 
41. Parra, M.E., C.B. Evans, and D.W. Taylor, Identification of Plasmodium falciparum 
histidine-rich protein 2 in the plasma of humans with malaria. Journal of Clinical 
Microbiology, 1991. 29(8): p. 1629-34. 
42. Foundation, B.M.G. Malaria - Strategy Overview. 2015  [cited 2015 10/20/2015]; Available 
from: http://www.gatesfoundation.org/What-We-Do/Global-Health/Malaria. 
43. Organization, W.H., World Malaria Report 2014, M. Chan, Editor 2014, World Health 
Organization: Geneva, Switzerland. 
 43 
 
44. Gay, F., et al., Direct acridine orange fluorescence examination of blood slides compared 
to current techniques for malaria diagnosis. Transactions of the Royal Society of Tropical 
Medicine and Hygiene, 1996. 90(5): p. 516-518. 
45. Singh, N. and N. Valecha, Evaluation of a rapid diagnostic test, 'Determine malaria pf', in 
epidemic-prone, forest villages of central India (Madhya Pradesh). Ann Trop Med 
Parasitol, 2000. 94(5): p. 421-7. 
46. Reyburn, H., et al., Rapid diagnostic tests compared with malaria microscopy for guiding 
outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ, 2007. 
334(7590): p. 403. 
47. Guerrant RL, W.D., Weller PF, Tropical infectious diseases: Principles, Pathogens & 
Practice, Volume 22006: Elsevier Churchill Livingston. 
48. Murray, C.K., et al., Update on rapid diagnostic testing for malaria. Clinical Microbiology 
Reviews, 2008. 21(1): p. 97-110. 
49. Diagnostics, W.H.O.C.f.D.C.U.S.F.f.I.N., Malaria rapid diagnostic test performance : 
Summary of results of WHO product testing of malaria RDTs : round 1-5 (2008-2013), 
2014, World Health Organization: Geneva. p. 28. 
50. Davis, K.M., et al., Enhancement of Malaria Rapid Diagnostic Tests Using a Magnetically-
Enabled Biomarker Extraction and Delivery System (mBEADS). Lab on a Chip (in review), 
2016. 
51. Yager, P., G.J. Domingo, and J. Gerdes, Point-of-care diagnostics for global health. Annu 
Rev Biomed Eng, 2008. 10: p. 107-44. 
52. Tangpukdee, N., et al., Malaria diagnosis: a brief review. Korean J Parasitol, 2009. 47(2): 
p. 93-102. 
53. Murray, C.K. and J.W. Bennett, [Not Available]. Interdiscip Perspect Infect Dis, 2009. 2009: 
p. 415953. 
54. Staines, H.M. and S. Krishna, Treatment and prevention of malaria : antimalarial drug 
chemistry, action, and use. Milestones in drug therapy2012, Basel: Springer. x , 315 p. 
55. Bell, D. and R.W. Peeling, Evaluation of rapid diagnostic tests: malaria. Nat Rev Microbiol, 
2006. 4(9 Suppl): p. S34-8. 
56. Wongsrichanalai, C., et al., A review of malaria diagnostic tools: microscopy and rapid 
diagnostic test (RDT). Am J Trop Med Hyg, 2007. 77(6 Suppl): p. 119-27. 
 
 
